MEDICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1201148, encodeId=2711120114862, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤学 经验分享：一个月，直接接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/26/e25d2604eccebad31f0e1363efd3f53d.jpg, createdBy=debc2479590, createdName=伊利亚特, createdTime=Thu Mar 10 09:15:53 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069803, encodeId=272c106980398, content=投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36705320705, createdName=148a9ddfm20(暂无昵称), createdTime=Sat Nov 13 08:09:22 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124814, encodeId=8bb82124814fc, content=请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Mon Apr 10 14:22:57 CST 2023, time=2023-04-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1194058, encodeId=13b311940582c, content=这个杂志要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=faf05446251, createdName=ms6000000228582470, createdTime=Wed Feb 16 15:56:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907210, encodeId=4a2d90e210da, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:16:54 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577936, encodeId=d7c65e7936d3, content=大家好～这个杂志是不是限制文章的字数和图片啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=691d2329289, createdName=tangsm, createdTime=Tue Oct 15 00:00:00 CST 2019, time=2019-10-15, status=1, ipAttribution=)]

2022-03-10 伊利亚特

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤学
经验分享：一个月，直接接收。

1 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1201148, encodeId=2711120114862, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤学 经验分享：一个月，直接接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/26/e25d2604eccebad31f0e1363efd3f53d.jpg, createdBy=debc2479590, createdName=伊利亚特, createdTime=Thu Mar 10 09:15:53 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069803, encodeId=272c106980398, content=投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36705320705, createdName=148a9ddfm20(暂无昵称), createdTime=Sat Nov 13 08:09:22 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124814, encodeId=8bb82124814fc, content=请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Mon Apr 10 14:22:57 CST 2023, time=2023-04-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1194058, encodeId=13b311940582c, content=这个杂志要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=faf05446251, createdName=ms6000000228582470, createdTime=Wed Feb 16 15:56:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907210, encodeId=4a2d90e210da, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:16:54 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577936, encodeId=d7c65e7936d3, content=大家好～这个杂志是不是限制文章的字数和图片啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=691d2329289, createdName=tangsm, createdTime=Tue Oct 15 00:00:00 CST 2019, time=2019-10-15, status=1, ipAttribution=)]

2021-11-13 148a9ddfm20(暂无昵称)

投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？

78 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1201148, encodeId=2711120114862, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤学 经验分享：一个月，直接接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/26/e25d2604eccebad31f0e1363efd3f53d.jpg, createdBy=debc2479590, createdName=伊利亚特, createdTime=Thu Mar 10 09:15:53 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069803, encodeId=272c106980398, content=投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36705320705, createdName=148a9ddfm20(暂无昵称), createdTime=Sat Nov 13 08:09:22 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124814, encodeId=8bb82124814fc, content=请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Mon Apr 10 14:22:57 CST 2023, time=2023-04-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1194058, encodeId=13b311940582c, content=这个杂志要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=faf05446251, createdName=ms6000000228582470, createdTime=Wed Feb 16 15:56:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907210, encodeId=4a2d90e210da, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:16:54 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577936, encodeId=d7c65e7936d3, content=大家好～这个杂志是不是限制文章的字数和图片啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=691d2329289, createdName=tangsm, createdTime=Tue Oct 15 00:00:00 CST 2019, time=2019-10-15, status=1, ipAttribution=)]

2023-10-19 1224e2e7m99(暂无昵称) 来自江苏省

审稿速度:2.0
偏重的研究方向：肿瘤
经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！

32 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1201148, encodeId=2711120114862, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤学 经验分享：一个月，直接接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/26/e25d2604eccebad31f0e1363efd3f53d.jpg, createdBy=debc2479590, createdName=伊利亚特, createdTime=Thu Mar 10 09:15:53 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069803, encodeId=272c106980398, content=投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36705320705, createdName=148a9ddfm20(暂无昵称), createdTime=Sat Nov 13 08:09:22 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124814, encodeId=8bb82124814fc, content=请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Mon Apr 10 14:22:57 CST 2023, time=2023-04-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1194058, encodeId=13b311940582c, content=这个杂志要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=faf05446251, createdName=ms6000000228582470, createdTime=Wed Feb 16 15:56:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907210, encodeId=4a2d90e210da, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:16:54 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577936, encodeId=d7c65e7936d3, content=大家好～这个杂志是不是限制文章的字数和图片啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=691d2329289, createdName=tangsm, createdTime=Tue Oct 15 00:00:00 CST 2019, time=2019-10-15, status=1, ipAttribution=)]

2022-06-16 ms7000001655187333

没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗

72 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1201148, encodeId=2711120114862, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤学 经验分享：一个月，直接接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/26/e25d2604eccebad31f0e1363efd3f53d.jpg, createdBy=debc2479590, createdName=伊利亚特, createdTime=Thu Mar 10 09:15:53 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069803, encodeId=272c106980398, content=投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36705320705, createdName=148a9ddfm20(暂无昵称), createdTime=Sat Nov 13 08:09:22 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124814, encodeId=8bb82124814fc, content=请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Mon Apr 10 14:22:57 CST 2023, time=2023-04-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1194058, encodeId=13b311940582c, content=这个杂志要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=faf05446251, createdName=ms6000000228582470, createdTime=Wed Feb 16 15:56:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907210, encodeId=4a2d90e210da, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:16:54 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577936, encodeId=d7c65e7936d3, content=大家好～这个杂志是不是限制文章的字数和图片啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=691d2329289, createdName=tangsm, createdTime=Tue Oct 15 00:00:00 CST 2019, time=2019-10-15, status=1, ipAttribution=)]

2023-04-10 ms9000001463682571 来自安徽省

请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急

49 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1201148, encodeId=2711120114862, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤学 经验分享：一个月，直接接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/26/e25d2604eccebad31f0e1363efd3f53d.jpg, createdBy=debc2479590, createdName=伊利亚特, createdTime=Thu Mar 10 09:15:53 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069803, encodeId=272c106980398, content=投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36705320705, createdName=148a9ddfm20(暂无昵称), createdTime=Sat Nov 13 08:09:22 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124814, encodeId=8bb82124814fc, content=请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Mon Apr 10 14:22:57 CST 2023, time=2023-04-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1194058, encodeId=13b311940582c, content=这个杂志要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=faf05446251, createdName=ms6000000228582470, createdTime=Wed Feb 16 15:56:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907210, encodeId=4a2d90e210da, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:16:54 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577936, encodeId=d7c65e7936d3, content=大家好～这个杂志是不是限制文章的字数和图片啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=691d2329289, createdName=tangsm, createdTime=Tue Oct 15 00:00:00 CST 2019, time=2019-10-15, status=1, ipAttribution=)]

2022-02-16 ms6000000228582470

这个杂志要版面费吗？

63 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1201148, encodeId=2711120114862, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤学 经验分享：一个月，直接接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/26/e25d2604eccebad31f0e1363efd3f53d.jpg, createdBy=debc2479590, createdName=伊利亚特, createdTime=Thu Mar 10 09:15:53 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069803, encodeId=272c106980398, content=投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36705320705, createdName=148a9ddfm20(暂无昵称), createdTime=Sat Nov 13 08:09:22 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124814, encodeId=8bb82124814fc, content=请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Mon Apr 10 14:22:57 CST 2023, time=2023-04-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1194058, encodeId=13b311940582c, content=这个杂志要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=faf05446251, createdName=ms6000000228582470, createdTime=Wed Feb 16 15:56:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907210, encodeId=4a2d90e210da, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:16:54 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577936, encodeId=d7c65e7936d3, content=大家好～这个杂志是不是限制文章的字数和图片啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=691d2329289, createdName=tangsm, createdTime=Tue Oct 15 00:00:00 CST 2019, time=2019-10-15, status=1, ipAttribution=)]

2020-12-12 1245a12em04(暂无昵称)

审稿速度:1.0 | 投稿命中率:25.0
经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%

150 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1201148, encodeId=2711120114862, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤学 经验分享：一个月，直接接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/26/e25d2604eccebad31f0e1363efd3f53d.jpg, createdBy=debc2479590, createdName=伊利亚特, createdTime=Thu Mar 10 09:15:53 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069803, encodeId=272c106980398, content=投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36705320705, createdName=148a9ddfm20(暂无昵称), createdTime=Sat Nov 13 08:09:22 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124814, encodeId=8bb82124814fc, content=请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Mon Apr 10 14:22:57 CST 2023, time=2023-04-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1194058, encodeId=13b311940582c, content=这个杂志要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=faf05446251, createdName=ms6000000228582470, createdTime=Wed Feb 16 15:56:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907210, encodeId=4a2d90e210da, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:16:54 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577936, encodeId=d7c65e7936d3, content=大家好～这个杂志是不是限制文章的字数和图片啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=691d2329289, createdName=tangsm, createdTime=Tue Oct 15 00:00:00 CST 2019, time=2019-10-15, status=1, ipAttribution=)]

2023-12-26 ms8000000049838423 来自北京

偏重的研究方向：基础肿瘤
经验分享：2023.10.13 submitted
2023.10.22 Under Review
2023.11.8 major revise
2023.12.17 resubmitted
2023.12.18 accept

19 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1201148, encodeId=2711120114862, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤学 经验分享：一个月，直接接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/26/e25d2604eccebad31f0e1363efd3f53d.jpg, createdBy=debc2479590, createdName=伊利亚特, createdTime=Thu Mar 10 09:15:53 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069803, encodeId=272c106980398, content=投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36705320705, createdName=148a9ddfm20(暂无昵称), createdTime=Sat Nov 13 08:09:22 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124814, encodeId=8bb82124814fc, content=请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Mon Apr 10 14:22:57 CST 2023, time=2023-04-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1194058, encodeId=13b311940582c, content=这个杂志要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=faf05446251, createdName=ms6000000228582470, createdTime=Wed Feb 16 15:56:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907210, encodeId=4a2d90e210da, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:16:54 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577936, encodeId=d7c65e7936d3, content=大家好～这个杂志是不是限制文章的字数和图片啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=691d2329289, createdName=tangsm, createdTime=Tue Oct 15 00:00:00 CST 2019, time=2019-10-15, status=1, ipAttribution=)]

2022-08-29 ms2000000713462597

审稿速度:1.0 | 投稿命中率:25.0
经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%

59 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1201148, encodeId=2711120114862, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤学 经验分享：一个月，直接接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/26/e25d2604eccebad31f0e1363efd3f53d.jpg, createdBy=debc2479590, createdName=伊利亚特, createdTime=Thu Mar 10 09:15:53 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069803, encodeId=272c106980398, content=投的稿子被改该杂志转到预印本的平台，如果被拒了会不会影响文章的二次投稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36705320705, createdName=148a9ddfm20(暂无昵称), createdTime=Sat Nov 13 08:09:22 CST 2021, time=2021-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124814, encodeId=8bb82124814fc, content=请问大家能分享一下自己的状态改变吗？我1号提交的，3号变成editor assigned，然后一周了一直没变，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Mon Apr 10 14:22:57 CST 2023, time=2023-04-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1194058, encodeId=13b311940582c, content=这个杂志要版面费吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=faf05446251, createdName=ms6000000228582470, createdTime=Wed Feb 16 15:56:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907210, encodeId=4a2d90e210da, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：攒人品，生信文章，一周被拒，拒搞理由是拒搞率80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:16:54 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577936, encodeId=d7c65e7936d3, content=大家好～这个杂志是不是限制文章的字数和图片啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=183, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=691d2329289, createdName=tangsm, createdTime=Tue Oct 15 00:00:00 CST 2019, time=2019-10-15, status=1, ipAttribution=)]

2019-10-15 tangsm

大家好～这个杂志是不是限制文章的字数和图片啊

183 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务